Page 150 - Sách năm 2022 - Fulltext - hieu final

TREATMENT RESULTS AND PROGRESS OF

NEWLY DIAGNOSED IMMUNE THROMBOCYTOPENIA PATIENTS

AT CHILDREN'S HOSPITAL 2 FROM JUNE 2020 TO MAY 2021

Tran Ngoc Huy Hoang , Bùi Quang Vinh
2
1
ABSTRACT
Introduction: Currently, the treatment of newly diagnosed Immune

Thrombocytopenia (ITP) has many updates and consensus based on a better understanding

of the pathogenesis. The classification of bleeding severity at the time of diagnosis helps to

guide the choice of appropriate treatment between non-pharmacological treatment and drug

intervention. Intravenous Corticosteroids and Immunoglobulins (IVIG) are the most used
measures in the treatment of ITP and evaluating the effectiveness after treatment in the first

3 months is a matter of concern.

Object: Determination of treatment characteristics of newly diagnosed ITP in

children at the Department of Hematology-Oncology, Children's Hospital 2 from June 2020

to May 2021.
Subjects and methods: Follow-up of 100 cases of pediatric patients admitted to the

Department of Hematology - Oncology at Children's Hospital 2 who were newly diagnosed

with ITP from June 1, 2020, to the May 30, 2021, meeting the inclusion and exclusion

criteria.

Results:100 pediatric patients (61 males and 39 females) with a median age of 6.32

months (IQR: 2.1-37.6) were graded for bleeding at admission: 75% have mild bleeding.
16% moderate bleeding and 9% severe bleeding; 4% of children received no-drug

treatment, 76 % of children treated with oral prednisone, 32% of children receiving

intravenous methylprednisolone and 20% of children treated with IVIG. The complete

response rate at first week of the treatment group with oral prednisone was 56.6%,

intravenous methylprednisolone was 59.4% and with IVIG was 55%. The rate of re-
hospitalization in the first 3 months was 10.5% with oral prednisone, 21.8% with

150